Medicine & Life Sciences
atosiban
16%
Cardiovascular Diseases
38%
Chronic Renal Insufficiency
12%
Cohort Studies
48%
Comorbidity
23%
Confidence Intervals
19%
Cost of Illness
11%
Cost-Benefit Analysis
54%
Costs and Cost Analysis
33%
Databases
22%
Delivery of Health Care
27%
Diabetes Complications
20%
Dipeptidyl-Peptidase IV Inhibitors
60%
Economics
11%
Embryo Transfer
13%
Fertilization in Vitro
24%
Glucagon-Like Peptide-1 Receptor
35%
Glucose
13%
Health Care Sector
11%
HIV
14%
Hypoglycemia
27%
Hypoglycemic Agents
33%
Insulin
20%
insulin, long-acting, human
16%
Kidney
17%
Long-Acting Insulin
43%
Longitudinal Studies
29%
Medication Adherence
16%
Metformin
37%
Pharmaceutical Preparations
11%
Polycystic Ovary Syndrome
32%
Population
34%
Pregnancy
11%
Pregnancy Outcome
25%
Propensity Score
23%
Proportional Hazards Models
14%
Quality of Life
40%
Quality-Adjusted Life Years
21%
rilpivirine drug combination dolutegravir
11%
Safety
16%
Sodium-Glucose Transport Proteins
30%
Sodium-Glucose Transporter 2 Inhibitors
21%
Stroke
16%
Therapeutics
23%
Triple Negative Breast Neoplasms
11%
Type 1 Diabetes Mellitus
21%
Social Sciences
brand name
6%
cardiovascular disease
6%
chronic illness
21%
comorbidity
18%
costs
8%
drug
7%
expenditures
6%
health
12%
health care
7%
Health Care System
5%
Healthcare
5%
leisure time
5%
medication
9%
performance
5%
quality of life
25%
Taiwan
14%
utility analysis
7%
